Survival rates

Survival rates for lymphoma are different for each type of lymphoma. They also depend on your overall health, the stage of your cancer and which treatments you are getting. To understand lymphoma survival rates, experts study many people with lymphoma to see how many are living five years after their diagnosis.

For stage 1 Hodgkin lymphoma, the chance of surviving at least five years is 92%. As the cancer spreads, the chances get lower. For stage 4 Hodgkin lymphoma, the chance of surviving at least five years is about 82%.

For stage 1 non-Hodgkin lymphoma, the chance of surviving at least five years is 87%. As the cancer spreads, the chances get lower. For stage 4 non-Hodgkin lymphoma, the chance of surviving at least five years is about 63%.

Keep in mind that survival statistics take five years to collect. The most recent survival rates include people who had lymphoma treatment more than five years ago. These people may not have had access to the latest treatments. Over the last few decades, lymphoma death rates have been falling and survival rates have been increasing.

Sept. 16, 2025

Living with lymphoma?

Connect with others like you for support and answers to your questions in the CAR-T Cell Therapy support group on Mayo Clinic Connect, a patient community.

CAR-T Cell Therapy Discussions

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

781 Replies Thu, Oct 02, 2025

Colleen Young, Connect Director
CAR-T Cell Therapy: Introduce yourself and connect with others

327 Replies Thu, Oct 02, 2025

martetom
Will soon have a Bone Marrow Transplant: What can I expect?

23 Replies Thu, Oct 02, 2025

See more discussions
  1. Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed Aug. 6, 2025.
  2. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Aug. 6, 2025.
  3. Primary CNS lymphoma treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed Aug. 6, 2025.
  4. Mycosis fungoides (including Sezary Syndrome) treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq. Accessed Aug. 6, 2025.
  5. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Aug. 6, 2025.
  6. Cancer stat facts: Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed Aug. 6, 2025.
  7. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  8. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  9. Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  10. Larson RA, et al. Tumor lysis syndrome: Prevention and treatment. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  11. Elsevier Point of Care. Clinical Overview: Febrile neutropenia in adults. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  12. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  13. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  14. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Aug. 6, 2025.
  15. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Aug. 6, 2025.